Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.03 and has seen 1.18 million shares traded in the recent trading session. The company, currently valued at $288.77M, closed the recent trade at $0.8 per share which meant it gained $0.03 on the day or 3.22% during that session. The LXRX stock price is -206.25% off its 52-week high price of $2.45 and 65.0% above the 52-week low of $0.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.42 million shares traded. The 3-month trading volume is 13.41 million shares.
The consensus among analysts is that Lexicon Pharmaceuticals Inc (LXRX) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Sporting 3.22% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LXRX stock price touched $0.8 or saw a rise of 1.22%. Year-to-date, Lexicon Pharmaceuticals Inc shares have moved -54.57%, while the 5-day performance has seen it change 10.34%. Over the past 30 days, the shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) have changed 20.49%. Short interest in the company has seen 38.83 million shares shorted with days to cover at 9.4.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 86.67% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -650.0% off the targeted high while a plunge would see the stock gain -650.0% from the levels at last check today..
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
The company’s shares have gained 9.88% over the past 6 months.
Earnings growth for 2025 is a modest 49.60% while over the next 5 years, the company’s earnings are expected to increase by 30.30%.
LXRX Dividends
Lexicon Pharmaceuticals Inc is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders own 1.17% of the company shares, while shares held by institutions stand at 74.93% with a share float percentage of 75.82%. Investors are also buoyed by the number of investors in a company, with Lexicon Pharmaceuticals Inc having a total of 165.0 institutions that hold shares in the company. The top two institutional holders are ARTAL GROUP S.A. with over 175.1 million shares worth more than $294.17 million. As of 2024-06-30, ARTAL GROUP S.A. held 56.3318% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 38.69 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.99 million and represent 12.4462% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Apr 30, 2025 , the former fund manager holds about 2.80% shares in the company for having 10.16 shares of worth $8.3 million while later fund manager owns 5.15 shares of worth $4.2 million as of Mar 31, 2025 , which makes it owner of about 1.42% of company’s outstanding stock.
